Home > Resources > Whitepapers > Nanotechnology

Nanotechnology

June 6, 2018

Nanotechnology is now a mature subject in terms of the basic science, and while there were many claims for what it could achieve 20 years ago when the funding in the area was beginning to ramp up, there is now much more realism in most areas of application. The application to medicine and healthcare is certainly now much more well defined. There have also been some harsh lessons learned in the past 15 years or so as to the limitations being set by regulation, professional and public acceptance and by the funding agencies, both public and private.

Spotlight

Microbiology & Quality Associates, Inc.

Microbiology & Quality Associates, Inc., located in the San Francisco Bay Area, is a service organization providing a variety of services to life sciences companies.

OTHER WHITEPAPERS

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | August 30, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embark.

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Understanding Single-Pass Tangential Flow Filtration and the New Era of Bioprocessing

whitePaper | December 22, 2022

Single-pass tangential flow filtration (SPTFF) technology from Pall Corporation is revolutionizing current and future bioprocessing platforms with its implementations in biotech, vaccine and plasma industries. Its features are protected by a portfolio of patents[1-6].

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).